{
    "id": 26988,
    "fullName": "KLK2 - FGFR2",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "KLK2-FGFR2 results from the fusion of KLK2 and FGFR2, leading to the activation of Mek/Erk and Akt signaling pathways in cell culture (PMID: 28802831, Cancer Res 2019;79(13 Suppl):Abstract nr 2206), and therefore, is predicted to lead to a gain of protein function. KLK2-FGFR2 has been identified in prostate cancer (PMID: 28802831).",
            "references": [
                {
                    "id": 16500,
                    "pubMedId": null,
                    "title": "Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2206"
                },
                {
                    "id": 9897,
                    "pubMedId": 28802831,
                    "title": "Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28802831"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3817,
        "geneSymbol": "KLK2",
        "terms": [
            "KLK2",
            "hGK-1",
            "hK2",
            "KLK2A2"
        ]
    },
    "variant": "KLK2 - FGFR2",
    "createDate": "09/13/2017",
    "updateDate": "10/18/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2263,
                "geneSymbol": "FGFR2",
                "terms": [
                    "FGFR2",
                    "BBDS",
                    "BEK",
                    "BFR-1",
                    "CD332",
                    "CEK3",
                    "CFD1",
                    "ECT1",
                    "JWS",
                    "K-SAM",
                    "KGFR",
                    "TK14",
                    "TK25"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 18853,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Infigratinib (BGJ398) treatment inhibited the proliferation of transformed cells expressing KLK2-FGFR2 in culture (Cancer Res 2019;79(13 Suppl):Abstract nr 2206).",
            "molecularProfile": {
                "id": 28355,
                "profileName": "KLK2 - FGFR2"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16500,
                    "pubMedId": null,
                    "title": "Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2206"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28355,
            "profileName": "KLK2 - FGFR2",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}